Gotowe bibliografie tematyczne / Type 1 diabetes mellitus

Gotowa bibliografia na temat „Type 1 diabetes mellitus”

Autor: Grafiati
Data publikacji: 4 czerwca 2021
Data aktualizacji: 14 marca 2023

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Spis treści

Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Type 1 diabetes mellitus”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Artykuły w czasopismach na temat "Type 1 diabetes mellitus"

1

Duarte, Nietsnie, Izabel Hazin, Carolina Vilar, Amanda Guerra, Luana Metta, Danielle Garcia i Rosália Freire. "INTELLIGENCE AND DIABETES MELLITUS TYPE 1". Psicologia, Saúde & Doença 18, nr 2 (25.07.2017): 462–73. http://dx.doi.org/10.15309/17psd180214.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Kaufman, F. R. "Type 1 Diabetes Mellitus". Pediatrics in Review 24, nr 9 (1.09.2003): 291–300. http://dx.doi.org/10.1542/pir.24-9-291.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Gregory, J. M., D. J. Moore i J. H. Simmons. "Type 1 Diabetes Mellitus". Pediatrics in Review 34, nr 5 (1.05.2013): 203–15. http://dx.doi.org/10.1542/pir.34-5-203.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Gregory, Justin M., Daniel J. Moore i Jill H. Simmons. "Type 1 Diabetes Mellitus". Pediatrics In Review 34, nr 5 (1.05.2013): 203–15. http://dx.doi.org/10.1542/pir.34.5.203.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Kaufman, Francine Ratner. "Type 1 Diabetes Mellitus". Pediatrics In Review 24, nr 9 (1.09.2003): 291–300. http://dx.doi.org/10.1542/pir.24.9.291.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Syed, Fatima Z. "Type 1 Diabetes Mellitus". Annals of Internal Medicine 175, nr 3 (marzec 2022): ITC33—ITC48. http://dx.doi.org/10.7326/aitc202203150.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Lee, Myung-Shik, i Kyoung-Ah Kim. "Type 1 Diabetes Mellitus". Journal of the Korean Medical Association 52, nr 7 (2009): 677. http://dx.doi.org/10.5124/jkma.2009.52.7.677.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Federico Bertuzzi, Roberto Verzaro, Vincenzo Provenzano i Camillo Ricordi. "Brittle Type 1 Diabetes Mellitus". Current Medicinal Chemistry 14, nr 16 (1.07.2007): 1739–44. http://dx.doi.org/10.2174/092986707781058922.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

You, Wei, Jianming Yang, Yanqun Liu, Wen Wang, Li Zhu, Wei Wang, Jun Yang i Fangyuan Chen. "Fulminant type 1 diabetes mellitus". Medicine 98, nr 5 (luty 2019): e14319. http://dx.doi.org/10.1097/md.0000000000014319.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

IMAGAWA, Akihisa, i Toshiaki HANAFUSA. "Fulminant Type 1 Diabetes Mellitus". Endocrine Journal 53, nr 5 (2006): 577–84. http://dx.doi.org/10.1507/endocrj.kr-72.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Rozprawy doktorskie na temat "Type 1 diabetes mellitus"

1

Dekki, Wenna Nancy. "Serum proteins in type 1 diabetes /". Stockholm, 2007. http://diss.kib.ki.se/2007/978-91-7357-057-2/.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Hoogma, Roeland Petrus Leonardus Maria. "Subcutaneous insulin infusion in type 1 diabetes mellitus". [S.l. : Amsterdam : s.n.] ; Universiteit van Amsterdam [Host], 2006. http://dare.uva.nl/document/29301.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Wong, Xing-Wei. "Model-Based Therapeutics for Type 1 Diabetes Mellitus". Thesis, University of Canterbury. Mechanical Engineering, 2008. http://hdl.handle.net/10092/1573.

Pełny tekst źródła
Streszczenie:
The incidence of Type 1 diabetes is growing yearly. Worryingly, the aetiology of the disease is inconclusive. What is known is that the total number of affected individuals, as well as the severity and number of associated complications are growing for this chronic disease. With increasing complications due to severity, length of exposure, and poor control, the disease is beginning to consume an increasingly major portion of healthcare costs to the extent that it poses major economic risks in several nations. Research has shown that intensive insulin therapy aimed at certain minimum glycosylated haemoglobin threshold levels reduces the incidence of complications by up to 76% compared to conventional insulin therapy. Moreover, the effects of such intensive therapy regimes over a 6.5y duration persists for at least 10y after, a so called metabolic memory. Thus, early intervention can slow the momentum of complications far more easily than later intervention. Early, safe, intensive therapy protocols offer potential solutions to the growing social and economic effects of diabetes. Since the 1970s, the artificial endocrine pancreas has been heralded as just this type of solution. However, no commercial product currently exists, and ongoing limitations in sensors and pumps have resulted in, at best, modest clinical advantages over conventional methods of insulin administration or multiple daily injection. With high upfront costs, high costs of consumables, significant complexity, and the extensive infrastructure and support required, these systems and devices are only used by 2-15% of individuals with Type 1 diabetes. Clearly, there is an urgent need to address the large majority of the Type 1 diabetes population using conventional glucose measurement and insulin administration. For these individuals, current conventional or intensive therapies are failing to deliver recommended levels of glycaemic control. This research develops an understanding of clinical glycaemic control using conventional insulin administration and glucose measurement techniques in Type 1 diabetes based on a clinically validated in silico virtual patient simulation. Based on this understanding, a control protocol for Type 1 diabetes that is relatively simple and clinically practical is developed. The protocol design incorporates physiological modelling and engineering techniques to adapt to individual patient clinical requirements. By doing so, it produces accurate, patient-specific recommendations for insulin interventions. Initially, a simple, physiological compartmental model for the pharmacokinetics of subcutaneously injected insulin is developed. While the absorption process itself is subject to significant potential variability, such models enable a real-time estimation of plasma insulin concentration. This information would otherwise be lacking in the clinical environment of outpatient Type 1 diabetes treatment due to the inconvenience, cost, and laboratory turnaround for plasma insulin measurements. Hence, this validated model offers significant opportunity to optimise therapy selection. An in silico virtual patient simulation tool is also developed. A virtual patient cohort is developed on patient data from a representative cohort of the broad diabetes population. The simulation tool is used to develop a robust, adaptive protocol for prandial insulin dosing against a conventional intensive insulin therapy, as well as a controls group representative of the general diabetes population. The effect on glycaemic control of suboptimal and optimal, prandial and basal insulin therapies is also investigated, with results matching clinical expectations. To gauge the robustness of the developed adaptive protocol, a Monte Carlo analysis is performed, incorporating realistic and physiological errors and variability. Due to the relatively infrequent glucose measurement in outpatient Type 1 diabetes, a method for identifying the diurnal cycle in effective insulin sensitivity and modelling it in retrospective patient data is also presented. The method consists of identifying deterministic and stochastic components in the patient effective insulin sensitivity profile. Circadian rhythmicity and sleep-wake phases have profound effects on effective insulin sensitivity. Identification and prediction of this rhythm is of utmost clinical relevance, with the potential for safer and more effective glycaemic control, with less frequent measurement. It is thus a means of further enhancing any robust protocol and making it more clinically practical to implement. Finally, this research presents an entire framework for the realistic, and rapid development and testing of clinical glycaemic control protocols for outpatient Type 1 diabetes. The models and methods developed within this framework allow rapid and physiological identification of time-variant, patient-specific, effective insulin sensitivity profiles. These profiles form the responses of the virtual patient and can be used to develop and robustly test clinical glycaemic control protocols in a broad range of patients. These effective insulin sensitivity profiles are also rich in dynamics, specifically those circadian in nature which can be identified, and used to provide more accurate glycaemic prediction with the potential for safer and more effective control.
Style APA, Harvard, Vancouver, ISO itp.
4

Carvalho, Tiago Filipe Cruz. "Type 1 diabetes mellitus effects on mitochondrial function". Master's thesis, Universidade de Aveiro, 2011. http://hdl.handle.net/10773/7520.

Pełny tekst źródła
Streszczenie:
Mestrado em Bioquímica-Métodos Biomuleculares
Despite type 1 diabetes mellitus being more rare, it has an autoimmune origin and appears early in life, greatly affecting its quality. With the aim of better understand the molecular mechanisms underlying the observed phenotypic alterations in the skeletal muscle from diabetic patients, it was planned an experimental protocol using 20 Wistar rats 8 weeks old, randomly divided in two groups (n=10). The animals from one group were injected with 60mg/Kg of streptozotocin (STZ), while the others were injected with vehicle buffer. Four months after STZ injection, rats were confirmed as diabetic, considering hyperglycemia and body weight loss. After animals sacrifice, gastrocnemius muscles were excised and used for mitochondria subpopulations (subsarcolemmal (SS) and intermyofibrillar (IMF)) isolation. mtDNA-to-muscle mass ratio suggest an increased biogenesis of SS mitochondria in the STZ animals, paralleled by a decreased protein content per mitochondrion, in opposite to the observed in IMF mitochondria. The BN-PAGE profile revealed a slight difference of the oxidative phosphorylation complexes organization between mitochondrial subpopulations, apparently not affected by STZ administration. Mitochondrial proteolysis analysis, evaluated through zymography, revealed two proteases with molecular weights around 15 and 25 KDa, with the smaller one presenting STZinduced significant decreased activity in IMF mitochondria. A similar behavior was observed for paraplegin, a subunit of m- AAA proteolytic system, and mitofilin, a protein involved in cristae organization. Interestingly, these protein levels were higher in SS mitochondria from diabetic animals. With this work it was verified that subsarcolemmal mitochondria are not so affected by STZ administration as IMF mitochondria. The decreased activity of the protein quality control system seems to be associated with the morphological and biochemical alterations observed in the mitochondria interspersed in fibrils.
Apesar de a diabetes tipo 1 ser uma das formas mais raras de diabetes mellitus, tem uma origem auto-imune e aparece precocemente na vida de um indivíduo afectando grandemente a qualidade da mesma. No sentido de melhor compreender os mecanismos moleculares subjacentes às alterações fenotípicas observadas no músculo esquelético dos pacientes diabéticos, delineou-se um protocolo experimental com 20 ratos Wistar com 8 semanas de idade, aleatoriamente divididos em dois grupos (n=10). Os animais de um dos grupos foram injectados com 60mg/Kg de streptozotocina (STZ), e os outros com veículo. Após 4 meses, os ratos injectados com STZ foram confirmados como diabéticos, tendo em consideração a hiperglicemia e a perda de massa corporal. Após o sacrifício dos animais foram retirados os músculos gastrocnemius, a partir dos quais foram isoladas as duas subpopulações mitocondriais (subsarcolemal (SS) e intermiofibrilar (IMF)). A análise da razão mtADN-massa muscular sugere que a administração de STZ induziu o aumento da biogénese mitocondrial SS associado a um decréscimo do teor proteico mitocondrial, ao contrário do observado nas mitocôndrias IMF. O perfil de BNPAGE revelou uma ligeira diferença entre a organização dos complexos da fosforilação oxidativa entre ambas as subpopulações mitocondriais, aparentemente não afectada pela administração de STZ. A análise da proteólise mitocondrial, efectuada por zimografia, evidenciou duas proteases com 15 e 25 KDa, tendo-se observado uma diminuição acentuada da actividade da protease com menor peso molecular nas mitocôndrias IMF dos animais diabéticos. Uma tendência semelhante foi observada para a expressão da subunidade paraplegina do sistema proteolítico m-AAA e para a mitofilina, uma proteína envolvida na organização da membrana interna mitocondrial. Curiosamente, nas mitocôndrias SS dos animais diabéticos verificaram-se níveis mais elevados destas proteínas. Com este estudo verificou-se que no gastrocnemius, as mitocôndrias IMF são mais afectadas pela diabetes mellitus tipo 1 do que as SS. A diminuição da actividade do sistema de controlo da qualidade proteica parece estar associada às alterações morfológicas e bioquímicas observadas nas mitocôndrias localizadas entre as fibrilas.
Style APA, Harvard, Vancouver, ISO itp.
5

Elfvin, Åkesson Karin. "Genetic analysis of type 1 diabetes /". Stockholm : Karolinska institutet, 2007. http://diss.kib.ki.se/2007/978-91-7357-321-4/.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Elrayah-Eliadarous, Hind. "Economic burden of diabetes on patients and their families in Sudan /". Stockholm, 2007. http://diss.kib.ki.se/2007/978-91-7357-450-1/.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Stavrou, Eftyhia P. "Functional losses in type 2 diabetes mellitus". Thesis, Queensland University of Technology, 2001. https://eprints.qut.edu.au/36771/1/36771_Digitised%20Thesis.pdf.

Pełny tekst źródła
Streszczenie:
Aims: Psychophysical tests such as Letter contrast sensitivity (CS) and flicker perimetry have been used to detect early functional losses in ocular disease such as age-related maculopathy (ARM) and in vascular disorders such as migraine. This study set out to determine the ability of these tests to detect early functional losses in type 2 diabetics with minimal or early diabetic retinopathy (DR). Methods: Subjects consisted of 20 patients with type 2 diabetes (duration, following diagnosis, ranging from 6 months to 18 years) and 24 age-matched normal controls. Letter CS, using the Pelli-Robson cha.ii, visual acuity (VA) using the standard high contrast Bailey-Lovie chart and monocular visual fields (VF) were measured. Static and flicker VF were measured using the Medmont M600 perimeter (MFA) and SIT A-standard fields using the Humphrey Field Analyser (HFA) were tested. Results: Letter CS was able to discriminate those diabetic subjects with none or early DR and those with and without ME from the control group, whereas VA was not able to detect any significant differences in visual function in these diabetic sub-groups compared to the control group. In terms of visual fields, both the pattern defect (PD) index and hill-ofvision profiles were analysed. In those with early onset of diabetes and in those with none/minimal DR, only the PD index obtained with the flicker technique was significantly worse than the control group. The hill-of-vision profiles showed that the PD loss in those with minimal DR when flicker perimetry was used, was due to a central depression close to fixation, whereas the MFA static and HFA profiles consisted of a general depression across the field. This indicated that the flicker technique is a more sensitive test than the static technique in determining central visual field defects in those with minor observable retinal changes. The inability of the HFA to detect changes to the macula region was thought to be due to the large grid spacing of the stimuli, as when the severity of retinopathy increased to a moderate level, the MFA static technique produced central losses which were not evident with the HFA. Conclusion: For diabetic patients who had either, a duration of diabetes of less than five years, or displayed only minimal or no DR or no ME, VF defects were only elicited with the use of the MFA flicker technique. Further functional losses in those with no or early, clinically detectable changes, were revealed by measuring Pelli-Robson Letter CS.
Style APA, Harvard, Vancouver, ISO itp.
8

Jamali, Reza. "Peripheral Hypoglycaemic Neuropathy in Type 1 Diabetic Rats : Morphologic and Metabolic Studies". Doctoral thesis, Linköping : Univ, 2006. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-7978.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Nordwall, Maria. "Long term complications in juvenile diabetes mellitus". Doctoral thesis, Linköping : Univ, 2006. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-6377.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Rydgren, Tobias. "Experimental Studies Aiming to Prevent Type 1 Diabetes Mellitus". Doctoral thesis, Uppsala University, Department of Medical Cell Biology, 2007. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-8292.

Pełny tekst źródła
Streszczenie:

Type 1 diabetes mellitus (T1DM) is an autoimmune disease in which T-cells and macrophages invade the islets of Langerhans and selectively destroy the insulin producing β-cells, either directly or through the secretion of e.g. cytokines and nitric oxide (NO). This thesis has studied possible strategies to prevent T1DM. In β-cells and macrophages, NO is produced by inducible nitric oxide synthase (iNOS).

In the first study, we found that 1400W, a highly selective inhibitor of iNOS could prevent interleukin (IL)-1β induced suppression of rat islet function in vitro, but not diabetes induced by multiple low dose streptozotocin (MLDS), a well established animal model for autoimmune diabetes, in vivo.

Next, we wanted to test a new type of high affinity blocker of IL-1 action, called IL-1 trap, in vitro. Here we found that an IL-1 trap could prevent the suppressive effects by IL-1β on rat pancreatic islet function. Also, it was sufficient to block the action of IL-1β to prevent islet cell death induced by a combination of IL-1β, tumor necrosis factor-α and interferon-γ.

In study III, a murine IL-1 trap was found to prolong islet graft survival in the recurrence of disease (ROD) model, a T1DM model that involves syngeneic transplantation of healthy pancreatic islets to diabetic nonobese diabetic mice. Mice treated with IL-1 trap displayed an increased mRNA level of the cytokine IL-4 in isolated spleen cells. This suggests a shift towards Th2-cytokine production, which in part could explain the results.

Finally, simvastatin an anti-hypercholesterolemic drug that possesses anti-inflammatory properties e.g. by interfering with transendothelial migration of leukocytes to sites of inflammation was studied. We found that the administration of simvastatin could delay, and in some mice prevent, the onset of MLDS-diabetes, and prolong islet graft survival in the ROD model.

Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Książki na temat "Type 1 diabetes mellitus"

1

Levy, David. Type 1 diabetes. Oxford: Oxford University Press, 2010.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Barbara, Simon. Type 1 diabetes in adults. Oxford: Oxford University Press, 2010.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Unaue, Emil R., i Hugh O. McDevitt. Immunopathogenesis of type 1 diabetes mellitus. London: Academic, 2009.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Bluestone, Jeffrey A., Mark Atkinson i Peter Arvan. Type 1 diabetes. Cold Spring Harbor, N.Y: Cold Spring Harbor Laboratory Press, 2012.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Gregory, Bock, Goode Jamie i Novartis Foundation, red. Defining optimal immunotherapies for type 1 diabetes. Chichester, UK: Wiley-Blackwell, 2008.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Feinglos, Mark N., i M. Angelyn Bethel, red. Type 2 Diabetes Mellitus. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-60327-043-4.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Kaufman, Francine Ratner. Medical management of type 1 diabetes. Wyd. 6. Alexandria: American Diabetes Association, 2012.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

W, Bode Bruce, i American Diabetes Association, red. Medical management of type 1 diabetes. Wyd. 5. Alexandria, Va: American Diabetes Association, 2008.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Léon, Aucoin, i Prideux Tristan, red. Handbook of type 1 diabetes mellitus: Etiology, diagnosis, and treatment. Hauppauge, N.Y: Nova Science Publishers, 2009.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

S, Eisenbarth George, red. Immunology of type 1 diabetes. Wyd. 2. New York: Kluwer Academic/Plenum Publishers, 2004.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Części książek na temat "Type 1 diabetes mellitus"

1

Sonawalla, Ambreen, i Rabab Jafri. "Type 1 Diabetes Mellitus". W Endocrine Conditions in Pediatrics, 307–11. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-52215-5_52.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Woo, Paula, i Kendra B. Baldwin. "Type 1 Diabetes Mellitus". W Adolescent Nutrition, 663–91. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-45103-5_22.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

O'Reilly, Caryl Ann. "Diabetes Mellitus Type 1". W Clinical Case Studies in Home Health Care, 399–410. West Sussex UK: John Wiley & Sons, Inc., 2013. http://dx.doi.org/10.1002/9781118785744.ch38.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Heller, Lois Jane, Celette Sugg Skinner, A. Janet Tomiyama, Elissa S. Epel, Peter A. Hall, Julia Allan, Lara LaCaille i in. "Type 1 Diabetes Mellitus". W Encyclopedia of Behavioral Medicine, 2012. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4419-1005-9_780.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

La Greca, Annette M., i Eleanor R. Mackey. "Type 1 Diabetes Mellitus". W Behavioral Approaches to Chronic Disease in Adolescence, 85–100. New York, NY: Springer New York, 2009. http://dx.doi.org/10.1007/978-0-387-87687-0_8.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

McArdle, Paul. "Type 1 diabetes mellitus". W Dietetic and Nutrition Case Studies, 106–10. Chichester, UK: John Wiley & Sons, Ltd, 2016. http://dx.doi.org/10.1002/9781119163411.ch28.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Buschur, Elizabeth O., i Stephanie Lawrence. "Diabetes Mellitus (Type 1)". W Care of Adults with Chronic Childhood Conditions, 131–47. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-43827-6_9.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Meneghini, Luigi. "Type 1 Diabetes Mellitus". W Encyclopedia of Behavioral Medicine, 2282–83. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-39903-0_780.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Arampatzis, Adamantios, Lida Mademli, Thomas Reilly, Mike I. Lambert, Laurent Bosquet, Jean-Paul Richalet, Thierry Busso i in. "Type 1 Diabetes Mellitus". W Encyclopedia of Exercise Medicine in Health and Disease, 883. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-540-29807-6_4566.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Bhansali, Anil, i Yashpal Gogate. "Type 1 Diabetes Mellitus". W Clinical Rounds in Endocrinology, 365–91. New Delhi: Springer India, 2015. http://dx.doi.org/10.1007/978-81-322-2398-6_16.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.

Streszczenia konferencji na temat "Type 1 diabetes mellitus"

1

Aprilia, Dinda, Eva Decroli, Alexander Kam, Afdol Rahmadi, Asman Manaf i Syafril Syahbuddin. "Sepsis in Type 1 Diabetes Mellitus with Diabetic Ketoacidosis". W The 2nd International Conference on Tropical Medicine and Infectious Disease. SCITEPRESS - Science and Technology Publications, 2019. http://dx.doi.org/10.5220/0009859200720074.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Nengroo, Irfan, Kumudu Pematilleke i Tanya Naydeva. "1316 Type 1 diabetes mellitus: early diagnosis and referral". W Royal College of Paediatrics and Child Health, Abstracts of the RCPCH Conference, Liverpool, 28–30 June 2022. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2022. http://dx.doi.org/10.1136/archdischild-2022-rcpch.458.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Ismaili, Doruntina, Fëllënza Spahiu, Lirije Beqiri i Afërdita Berisha. "Nursing Care in Children with Type 1 Diabetes Mellitus". W University for Business and Technology International Conference. Pristina, Kosovo: University for Business and Technology, 2018. http://dx.doi.org/10.33107/ubt-ic.2018.370.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Mohammed, Ahmed, i Alzahraa saber. "Effect of Parvovirus B19 in Diabetes Mellitus Type 1". W Proceedings of 2nd International Multi-Disciplinary Conference Theme: Integrated Sciences and Technologies, IMDC-IST 2021, 7-9 September 2021, Sakarya, Turkey. EAI, 2022. http://dx.doi.org/10.4108/eai.7-9-2021.2314785.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Chaofeng Yan, Youqing Wang i Xifa Sun. "Predictive-retrospective proportional glycemic control for type 1 diabetes mellitus". W 2013 ICME International Conference on Complex Medical Engineering (CME 2013). IEEE, 2013. http://dx.doi.org/10.1109/iccme.2013.6548336.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Rodrigues, Fabiana. "Psychotherapy Intervention With Hypnosis In Patients With Type 1 Diabetes Mellitus". W 5th International Congress on Clinical & Counselling Psychology. Cognitive-crcs, 2017. http://dx.doi.org/10.15405/epsbs.2017.05.10.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Morales-Contreras, Jonatan, E. Ruiz-Velazquez i J. A. Garcia-Rodriguez. "Robust glucose control via μ-synthesis in type 1 diabetes mellitus". W 2017 IEEE International Autumn Meeting on Power, Electronics and Computing (ROPEC). IEEE, 2017. http://dx.doi.org/10.1109/ropec.2017.8261671.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Leon, Blanca S., Alma Y. Alanis, Edgar N. Sanchez, Fernando Ornelas-Tellez i Eduardo Ruiz-Velazquez. "Neural inverse optimal control applied to type 1 diabetes mellitus patients". W 2012 IEEE 3rd Latin American Symposium on Circuits and Systems (LASCAS). IEEE, 2012. http://dx.doi.org/10.1109/lascas.2012.6180310.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Lehmann, E. D., T. Deutsch, E. R. Carson i P. H. Sonksen. "A simulator of glucose-insulin interaction in type 1 diabetes mellitus". W 1992 14th Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE, 1992. http://dx.doi.org/10.1109/iembs.1992.5761298.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Lehmann, Deutsch, Carson i Sonksen. "A Simulator Of Glucose-insulin Interaction In Type 1 Diabetes Mellitus". W Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE, 1992. http://dx.doi.org/10.1109/iembs.1992.594640.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.

Raporty organizacyjne na temat "Type 1 diabetes mellitus"

1

Luan, Sisi, Wenke Cheng, Chenglong Wang, Hongjian Gong i Jianbo Zhou. Impact of glucagon-like peptide 1 analogs on cognitive function among patients with type 2 diabetes mellitus. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, czerwiec 2022. http://dx.doi.org/10.37766/inplasy2022.6.0015.

Pełny tekst źródła
Streszczenie:
Review question / Objective: Diabetes is an independent risk factor for cognitive impairment. Little is known regarding the neuroprotective effects of glucagon-like peptide 1 (GLP-1) analogs on type 2 diabetes mellitus (T2DM).Here, the study aim to assess the impact of GLP-1 on general cognition function among patients with T2DM. Eligibility criteria: Inclusion criteria were as follows: (1) an original article was recently published in English, (2) the population included subjects diagnosed with diabetes at baseline, (3) GLP-1 analogs is a single formulation rather than a fixed dose combination, (4) GLP-1 analogs were compared with no GLP-1 use or placebo or self-control before treatment, (5) the duration of antidiabetic agent use was 12 weeks or more, and (6) it provided quantitative measures of general cognitive function assessed by MMSE or MoCA. Exclusion criteria were as follows: (1) the publication was a review, case report, animal study, or letter to the editor, (2) the study did not clearly define clinical outcomes, (3) the authors could not provide valid data after being contacted, (4) duplicated data.
Style APA, Harvard, Vancouver, ISO itp.
2

Silva, Rodrigo Ribeiro e., Mateus de Miranda Gauza, Julia Opolski Nunes da Silva Opolski i Maria Eduarda Schramm Guisso. Once-Weekly Insulin Icodec vs Once-Daily Insulin Glargine U100 for Type 2 Diabetes: A Meta-analysis of Phase 2 Randomized Controlled Trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, maj 2022. http://dx.doi.org/10.37766/inplasy2022.5.0102.

Pełny tekst źródła
Streszczenie:
Review question / Objective: To compare Once-Weekly Insulin Icodec and Once-Daily Insulin Glargine U100 in patients with Type 2 Diabetes Mellitus using oral hypoglycemic drugs in need of insulin therapy. Condition being studied: Patients with Diabetes Mellitus Type 2 using oral hypoglycemic drugs in need for basal insulin. Eligibility criteria: Inclusion in this meta-analysis was restricted to studies that met all the following criteria: (1) randomized trials; (2) comparing the use once weekly insulin icodec to once daily insulin glargine; (3) enrolling patients with type 1 or type 2 diabetes mellitus; (4) evaluating any of the desired outcomes; (4) articles in written on english language. We excluded studies with (1) no control group; (2) overlapping studies population; clinical trial register entry only; (3) non-human studies and (4) studies reported only as abstracts.
Style APA, Harvard, Vancouver, ISO itp.
3

Deo, Salil, David McAllister, Naveed Sattar i Jill Pell. The time-varying cardiovascular benefits of glucagon like peptide-1 agonist (GLP-RA)therapy in patients with type 2 diabetes mellitus: A meta-analysis of multinational randomized trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, lipiec 2021. http://dx.doi.org/10.37766/inplasy2021.7.0097.

Pełny tekst źródła
Streszczenie:
Review question / Objective: P - patients with type 2 diabetes melllitus already receiving routine medical therapy; I - patients receiving glucagon like peptide 1 receptor agonist (GLP1 receptor agonist) therapy (semaglutide, dulaglutide, liraglutide, exenatide, lixisenatide, efpeglenatide, abiglutide); C - patients receiving standard therapy for diabetes mellitus but not receiving GLP1 agonist therapy; O - composite end point as per invididual trial, cardiovascular mortality, all-cause mortality, myocardial infarction, stoke. Condition being studied: Type 2 diabetes mellitus. Study designs to be included: Randomised controlled trials which enroll a large number of patients (defined as > 500) and are multinational in origin. Studies included will need to have published Kaplan and Meier curves for the end-points presented in the manuscript.
Style APA, Harvard, Vancouver, ISO itp.
4

Wang, Wanqing, Fei Huang i Chunchao Han. Efficacy of Regimens in the Treatment of Latent Autoimmune Diabetes in Adults: A Network Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, październik 2022. http://dx.doi.org/10.37766/inplasy2022.10.0072.

Pełny tekst źródła
Streszczenie:
Review question / Objective: Efficacy of Regimens in the Treatment of Latent Autoimmune Diabetes in Adults: A Network Meta-Analysis. Condition being studied: Latent autoimmune diabetes mellitus (LADA) in adults is a highly heterogeneous autoimmune disease with clinical and genetic characteristics between Type 1 Diabetes（T1DM） and Type 2 Diabetes（T2DM）, and therefore there are no uniform criteria for the selection of therapeutic agents. We conducted a web-based meta analysis to evaluate the efficacy of various therapeutic agents for LADA by comparing their effects on various indicators reflecting LADA disease.
Style APA, Harvard, Vancouver, ISO itp.
5

yu, luyou, jinping yang, xi meng i yanhua ling. Efficacy and safety of acupuncture combined with probiotics in the treatment of type 2 diabetes mellitus with intestinal microbiota disorder: A protocol for systematic review and meta analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, wrzesień 2022. http://dx.doi.org/10.37766/inplasy2022.9.0001.

Pełny tekst źródła
Streszczenie:
Review question / Objective: Efficacy and safety of acupuncture combined with probiotics in the treatment of type 2 diabetes mellitus with intestinal microbiota disorder: A protocol for systematic review and meta analysis. Eligibility criteria: 1.The literatures of type 2 diabetes patients were included without restriction on gender, age, race, disease course and blood glucose control of the subjects. 2. The relevant literatures included in human intestinal flora do not strictly restrict the test methods and key indicators of fecal specimens. 3. Relevant literatures with no statistically significant difference in general data between the experimental group and the control group were included. 4.There is no restriction on whether blind method or distributive hiding method is used to include Chinese and English literatures whose research type is correlation study. 5. References that clearly indicated standard deviation (SD), mean value or which could be calculated by formula were included.
Style APA, Harvard, Vancouver, ISO itp.
6

Larcom, Barbara, Rosemarie Ramos, Lisa Lott, J. M. McDonald, Mark True, Michele Tavish, Heidi Beason, Lee Ann Zarzabel, James Watt i Debra Niemeyer. Genetic Risk Conferred from Single Nucleotide Polymorphisms Towards Type II Diabetes Mellitus. Fort Belvoir, VA: Defense Technical Information Center, luty 2013. http://dx.doi.org/10.21236/ada573655.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Almigbal, Turky, Sarah alzarah, Flwah aljanoubi, Nouryah Alhafez, Munirah Aldawsari, Zahraa Alghadeer i Mohammed Batais. Clinical Inertia in the Management of Type 2 Diabetes Mellitus: A systematic Review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, wrzesień 2022. http://dx.doi.org/10.37766/inplasy2022.9.0068.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Wang, Wei, i Yi Wu. Prediction models for diabetic retinopathy development in type 2 diabetes mellitus patients: a systematic review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, marzec 2022. http://dx.doi.org/10.37766/inplasy2022.3.0089.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Moskalenko, O. L., O. V. Smirnova, E. V. Kasparov i I. E. Kasparova. PSYCHOLOGICAL FEATURES OF PATIENTS WITH TYPE. Science and Innovation Center Publishing House, 2021. http://dx.doi.org/10.12731/2658-4034-2021-12-4-2-349-356.

Pełny tekst źródła
Streszczenie:
The article is devoted to the study of psychoemotional characteristics of patients with diabetes mellitus. Conducting psychological techniques, testing, questioning patients will reveal anxiety-depressive states and psychological characteristics of patients with type I diabetes and type II diabetes for successful disease control. It is necessary to strive for the examination of such patients with an individual approach for each. To improve the quality of life of such patients, it is necessary to search for effective approaches in the education system of patients with type I diabetes and type II diabetes with the participation of psychologists.
Style APA, Harvard, Vancouver, ISO itp.
10

Trucco, Massimo. Safe Gene Therapy for Type 1 Diabetes. Fort Belvoir, VA: Defense Technical Information Center, październik 2012. http://dx.doi.org/10.21236/ada612662.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Możesz być także zainteresowany rozszerzonymi bibliografiami na temat „Type 1 diabetes mellitus” dla poszczególnych typów źródeł:
Artykuły w czasopismach Rozprawy doktorskie Książki
Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!

Do bibliografii